Are Kynurenines Accomplices or Principal Villains in Dementia? Maintenance of Kynurenine Metabolism
Worldwide, 50 million people suffer from dementia, a group of symptoms affecting cognitive and social functions, progressing severely enough to interfere with daily life.
Masaru Tanaka +2 more
doaj +1 more source
Combined Cyclosporin A and Hypothermia Treatment Inhibits Activation of BV-2 Microglia but Induces an Inflammatory Response in an Ischemia/Reperfusion Hippocampal Slice Culture Model [PDF]
Introduction: Hypothermia attenuates cerebral ischemia-induced neuronal cell death associated with neuroinflammation. The calcineurin inhibitor cyclosporin A (CsA) has been shown to be neuroprotective by minimizing activation of inflammatory pathways.
Berger, Felix +5 more
core +1 more source
CX3CL1 in Early Detection of Alzheimer's Disease: Plasma Dynamics Across Age and Disease Stages
ABSTRACT Backgrounds Alzheimer's disease (AD) is characterized by amyloid‐beta plaques, tau tangles, and neuroinflammation. C‐X3‐C motif chemokine ligand 1 (CX3CL1, also known as fractalkine), a neuroimmune chemokine implicated in AD pathogenesis, shows inconsistent alterations in plasma/serum across studies.
Ling Wang +6 more
wiley +1 more source
Effect of nicotine on the energy metabolism of substantia nigra cells in mptp-induced Parkinson’s disease [PDF]
Objective(s): Parkinson’s disease (PD) is a progressive neurodegenerative disorder affecting millions globally, with no current cure despite extensive research efforts.
Nikoloz Zhgenti +6 more
doaj +1 more source
Dehydroepiandrosterone sulfate (DHEAS) is neuroprotective when administered either before or after injury in a focal cortical cold lesion model [PDF]
Dehydroepiandrosterone and its sulfate (DHEAS) are sex hormone precursors that exert marked neurotrophic and/or neuroprotective activity in the central nervous system.
Dobszay B., Gábor +8 more
core
FeDSNP‐Pa, a metallized nanoparticle loaded with sodium pyruvate (Pa), exerts triple therapeutic effects by scavenging reactive oxygen species (ROS), suppressing inflammatory responses, and inhibiting pyroptosis signaling pathways. This multifunctional neuroprotective strategy protecting retinal ganglion cells (RGCs) from elevated intraocular pressure ...
Yukun Wu +5 more
wiley +1 more source
Neuroprotective Treatments in Parkinson’s Disease
Parkinson’s disease (PD) is a progressive disease due to dopaminergic cell loss in the substantia nigra and dopaminergic terminal lost in the striatum, which is the projection area of substantia nigra. It is characterized by resting tremor, bradykinesia,
Elif, Gul, Banu Cahide
doaj +1 more source
Anti-oxidants in Parkinson's disease therapy: a critical point of view [PDF]
Parkinson's disease (PD) is a degenerative neurological syndrome, which is characterized by the preferential death of dopaminergic (DAergic) neurons in the SubstantiaNigra.
Beltramini, Mariano +3 more
core +2 more sources
Drug‐Free Thrombolysis Mediated by Physically Activated Micro/Nanoparticles
Overview of particle‐mediated thrombolytic effects (thermal, mechanical, and chemical) and their activating physical stimuli (light, ultrasound, and magnetic field) in drug‐free thrombolysis. ABSTRACT Thrombus‐associated disorders rank among the world's leading causes of death, with ischemic heart disease and stroke as the main contributors.
Pierre Sarfati +2 more
wiley +1 more source
Drosophila modifier screens to identify novel neuropsychiatric drugs including aminergic agents for the possible treatment of Parkinson's disease and depression. [PDF]
Small molecules that increase the presynaptic function of aminergic cells may provide neuroprotection in Parkinson's disease (PD) as well as treatments for attention deficit hyperactivity disorder (ADHD) and depression.
Biedermann, T +13 more
core +2 more sources

